Search results for "Follicle Stimulating Hormone"

showing 10 items of 51 documents

Apolipoprotein B is regulated by gonadotropins and constitutes a predictive biomarker of IVF outcomes

2016

Background Follicular fluid (FF) is an important micro-environment influencing oocyte growth, its development competence, and embryo viability. The FF content analysis allows to identify new relevant biomarkers, which could be predictive of in vitro fertilization (IVF) outcomes. Inside ovarian follicle, the amount of FF components from granulosa cells (GC) secretion, could be regulated by gonadotropins, which play a major role in follicle development. Methods This prospective study included 61 female undergoing IVF or Intra-cytoplasmic sperm injection (ICSI) procedure. Apolipoprotein B (APOB) concentrations in follicular fluid and APOB gene and protein expression in granulosa cells from rep…

0301 basic medicineApolipoprotein Bmedicine.medical_treatment[SDV]Life Sciences [q-bio]Human follicular fluidOocyte RetrievalChorionic GonadotropinHuman chorionic gonadotropinFollicle-stimulating hormone0302 clinical medicineEndocrinologyProspective Studies030219 obstetrics & reproductive medicinebiologyObstetrics and Gynecology[SDV] Life Sciences [q-bio]Treatment Outcomemedicine.anatomical_structureFemalelipids (amino acids peptides and proteins)Apolipoprotein BEmbryo qualityAdultmedicine.medical_specialtyendocrine systemEmbryonic DevelopmentFertilization in Vitro03 medical and health sciencesOvulation InductionInternal medicinemedicineIVF outcomesHumansOvarian follicleApolipoproteins BHuman granulosa cellsGranulosa CellsIn vitro fertilisation[ SDV ] Life Sciences [q-bio]ResearchEmbryo MammalianOocyteFollicular fluidFollicular Fluid030104 developmental biologyEndocrinologyReproductive MedicineFertilizationbiology.proteinFollicle Stimulating HormoneBiomarkersGonadotropinsDevelopmental BiologyReproductive Biology and Endocrinology
researchProduct

Design and protocol of Estrogenic Regulation of Muscle Apoptosis (ERMA) study with 47 to 55-year-old women's cohort : novel results show menopause-re…

2018

Supplemental Digital Content is available in the text

0301 basic medicineOncologyestradiolivaihdevuodetNeutrophilsBlood count0302 clinical medicineSurveys and QuestionnairesFSHLongitudinal Studiesmenopausal status2. Zero hungerEstradiolvalkosolutApplied MathematicsObstetrics and Gynecologyta3141ta3142Middle AgedMenstruation3. Good health17β-EstradiolMenopauseCohortComputingMethodologies_DOCUMENTANDTEXTPROCESSINGFemaleMenopauselihaskuntoestrogeenitmedicine.medical_specialtyGeneral MathematicsAffect (psychology)Statistics Nonparametric03 medical and health sciencesohjelmoitunut solukuolema17b-Estradiolneutrophil-to-lymphocyte ratioInternal medicinemedicineHumansLymphocyte CountAnalysis of VarianceChi-Square Distributionbusiness.industryOriginal Articlesleucocyte countmedicine.diseaseCross-Sectional Studies030104 developmental biologyApoptosisMultivariate AnalysisLinear Modelsblood viscosityFollicle Stimulating Hormonebusiness030217 neurology & neurosurgeryFollow-Up StudiesHormoneMenopause: The Journal of The North American Menopause Society
researchProduct

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor–Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Ta…

2016

Purpose To describe estradiol (E2), estrone (E1), and estrone sulfate (E1S) levels during the first year of monthly triptorelin plus exemestane or tamoxifen and to assess possible suboptimal suppression while receiving exemestane plus triptorelin. Patients and Methods Premenopausal patients with early breast cancer on the Suppression of Ovarian Function Trial who selected triptorelin as the ovarian suppression method and were randomly assigned to exemestane plus triptorelin or tamoxifen plus triptorelin were enrolled until the target population of 120 patients was reached. Blood sampling time points were 0, 3, 6, 12, 18, 24, 36, and 48 months. Serum estrogens were measured with a highly sen…

Adult0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyAntineoplastic Agents HormonalEstronemedicine.drug_classBreast NeoplasmsEstrone03 medical and health scienceschemistry.chemical_compoundFollicle-stimulating hormone0302 clinical medicineBreast cancerExemestaneInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansGynecologyTriptorelin PamoateEstradiolbusiness.industryOvaryEstrogensORIGINAL REPORTSLuteinizing Hormonemedicine.diseaseTriptorelinAndrostadienesTamoxifen030104 developmental biologyOncologychemistryChemotherapy AdjuvantEstrogen030220 oncology & carcinogenesisFemaleFollicle Stimulating HormonebusinessTamoxifenmedicine.drugBlood samplingJournal of Clinical Oncology
researchProduct

Increased anti-Mullerian hormone levels and ovarian size in a subgroup of women with functional hypothalamic amenorrhea: further identification of th…

2016

Functional hypothalamic amenorrhea is a disorder characterized by cessation of menstrual cycles in the absence of organic disease. In most patients, it occurs in adult life after a stressful event and may be related to a condition of mild chronic energy deprivation. The endocrine pattern is characterized by low estrogen levels with an absent response to a progestogen challenge test and low-normal gonadotropin levels. A few studies have shown that some of these women may have some features of polycystic ovary syndrome; these features include an increased androgen response to gonadotropins, increased anti-Mullerian hormone levels, and altered ovarian morphology or increased ovarian size. Thes…

AdultAnti-Mullerian Hormoneendocrine systemmedicine.medical_specialtyendocrine system diseases030209 endocrinology & metabolismOvaryOrganic diseaseHypothalamic disease03 medical and health sciencesFollicle-stimulating hormoneYoung Adult0302 clinical medicineInternal medicinemedicineHumansTestosteroneAmenorrheaRetrospective Studies030219 obstetrics & reproductive medicinebiologybusiness.industryOvaryAndrostenedioneObstetrics and GynecologyAnti-Müllerian hormoneDehydroepiandrosteroneOrgan SizeLuteinizing Hormonemedicine.diseasePolycystic ovaryEndocrinologymedicine.anatomical_structureCase-Control Studiesbiology.proteinAmenorrheaFemalemedicine.symptomFollicle Stimulating HormoneLuteinizing hormonebusinessHypothalamic DiseasesPolycystic Ovary SyndromeAmerican journal of obstetrics and gynecology
researchProduct

Features of polycystic ovary syndrome (PCOS) in women with functional hypothalamic amenorrhea (FHA) may be reversible with recovery of menstrual func…

2017

Since features of polycystic ovary syndrome (PCOS) have been found to be prevalent in women with functional hypothalamic amenorrhea (FHA), we wished to determine what happens to these features after recovery of menstrual function in FHA Design: Prospective cohort study. Twenty-eight women with FHA and 30 age-matched ovulatory controls were studied.Twenty-eight women with FHA and 30 age-matched ovulatory controls were studied. We measured serum estradiol, LH, FSH, testosterone, DHEAS, anti-Mullerian hormone (AMH), body mass index, and ovarian morphology on transvaginal ultrasound.At baseline, 12 of the 28 women (43%) had increased AMH (4.7 ng/mL), and higher testosterone and larger ovaries c…

AdultAnti-Mullerian Hormoneendocrine systemmedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismHypothalamic amenorrheaYoung Adult03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicinemedicineHumansTestosteroneProspective StudiesAmenorrheaUltrasonography030219 obstetrics & reproductive medicineEstradiolDehydroepiandrosterone Sulfatebusiness.industryPolycystic ovary syndrome (PCOS)OvaryObstetrics and GynecologyTestosterone (patch)Luteinizing Hormonemedicine.diseasePolycystic ovaryhumanitiesMenstruationEndocrinologyOvarian morphologyFemaleFollicle Stimulating HormonebusinessHypothalamic DiseasesPolycystic Ovary SyndromeGynecological Endocrinology
researchProduct

The endocrine pattern of late onset adrenal hyperplasia (21-hydroxylase deficiency)

1984

We describe 5 adult women with severe hirsutism due to late onset 21-hydroxylase deficiency. Diagnosis was performed on the finding of high serum 17-hydroxyprogesterone (17OHP) levels with a marked hyperresponse to an ACTH test. The endocrine study showed in most patients a gonadotropin behavior similar to that observed in classical polycystic ovary (PCO) syndrome. Prolactin levels were slightly increased in basal conditions and presented an exaggerated response to TRH stimulation.

AdultHirsutismendocrine systemmedicine.medical_specialtyAdolescentmedicine.drug_classEndocrinology Diabetes and MetabolismLate onsetEndocrinologyAdrenocorticotropic HormoneInternal medicineHydroxyprogesteronesmedicineHumansEndocrine systemGonadal Steroid HormoneshirsutismAdrenal Hyperplasia Congenitalbiologybusiness.industry17-alpha-HydroxyprogesteroneVirilization21-HydroxylaseLuteinizing Hormonemedicine.diseasePolycystic ovaryProlactinProlactinEndocrinologySteroid Hydroxylasesbiology.proteinFemaleSteroid 21-HydroxylaseFollicle Stimulating Hormonemedicine.symptomGonadotropinbusinesshormones hormone substitutes and hormone antagonistsJournal of Endocrinological Investigation
researchProduct

Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis

2011

Objective: To analyze the impact of LH administration on cycle outcome in ovarian stimulation with GnRH antagonists. Design: Randomized, open-label, controlled trial performed in two age subgroups. Recombinant (r) FSH versus rFSH + rLH administration was compared. Setting: University-affiliated private infertility clinic. Patient(s): Up to 35 years old (n = 380) and aged 36 to 39 years (n = 340), undergoing their first or second IVF cycle. Intervention(s): Recombinant LH administration since stimulation day 1. Main Outcome Measure(s): Implantation rate, ongoing pregnancy rate. Result(s): In the young population, implantation rates were similar: 27.8% versus 28.6%, odds ratio (OR) 1.03 (95% …

AdultInfertilitymedicine.medical_specialtyPregnancy Ratemedicine.drug_classmedicine.medical_treatmentGonadotropin-releasing hormone antagonistGonadotropin-Releasing HormoneOvulation InductionPregnancymedicineGnRH antagonistHumansEmbryo ImplantationSperm Injections IntracytoplasmicGynecologyPregnancyIn vitro fertilisationbusiness.industryObstetrics and GynecologyOdds ratioLuteinizing Hormonemedicine.diseaseRecombinant ProteinsConfidence intervalPregnancy rateReproductive Medicineluteinizing hormoneDrug Therapy CombinationFemaleOvarian stimulationFollicle Stimulating HormoneLuteinizing hormonebusinessInfertility Femalein vitro fertilizationMaternal Age
researchProduct

Recombinant follicle stimulating hormone stimulation in poor responders with normal basal concentrations of follicle stimulating hormone and oestradi…

1999

A total of 30 young infertile patients who exhibited a poor response in two previous consecutive cycles, despite having normal basal follicle stimulating hormone (FSH) and oestradiol concentrations, were invited to participate in a prospective randomized study comparing the clinical efficacy of recombinant (rFSH) and urinary (uFSH) follicle stimulating hormone. An evaluation of the total dose used (3800 IU versus 4600 IU, P < 0.05) and duration of treatment (10.2 days versus 13.2 days, P < 0.05) showed a significantly shorter treatment period as well as a significantly lower total dose of FSH required to induce ovulation successfully in the group of patients treated with rFSH. Significantly…

AdultInfertilitymedicine.medical_specialtymedicine.drug_classUrinary systemmedia_common.quotation_subjectBiologyBasal (phylogenetics)Follicle-stimulating hormoneOvulation InductionPregnancyInternal medicinemedicineHumansEmbryo ImplantationProspective StudiesOvulationmedia_commonPregnancyEstradiolRehabilitationPregnancy OutcomeObstetrics and Gynecologymedicine.diseaseRecombinant ProteinsEndocrinologyReproductive MedicineEstrogenFemaleFollicle Stimulating HormoneGonadotropinHuman Reproduction
researchProduct

Gonadotropin Secretion in Eugonadotropic Human Males and Postmenopausal Females Under Long Term Application of a Potent Analog of Gonadotropin-Releas…

1978

Long-acting analogs are of special interest in long-term treatment with gonadotropin-releasing hormone (GnRH). However, inhibitory effects of agonist analogs on gonadotropin secretion or on reproductive processes have been observed in rats as well as in human males. Since these inhibitory effects seem to be dose-related, we checked the findings for d-Leu 6 -des-Gly 10 -GnRH-ethylamide within the dose range proposed by us for treatment. In six eugonadotropic human males, a significant decrease of luteinizing hormone and follicle-stimulating hormone responsiveness to a standard dose of GnRH and significant decrease of testosterone basal secretion were observed after 2 and 4weeks of subcutaneo…

AdultMaleAgonistendocrine systemmedicine.medical_specialtyTime Factorsmedicine.drug_classInjections SubcutaneousGonadotropin-releasing hormoneHuman MalesBiologyGonadotropin-Releasing HormoneBasal (phylogenetics)Internal medicinemedicineHumansTestosteroneAdministration IntranasalTestosteroneObstetrics and GynecologyLuteinizing HormoneGonadotropin secretionEndocrinologyReproductive MedicineFemaleFollicle Stimulating HormoneMenopauseLuteinizing hormonePituitary Hormone-Releasing Hormoneshormones hormone substitutes and hormone antagonistsHormoneFertility and Sterility
researchProduct

Validation of the German version of the ‘Hypogonadism Related Symptom Scale’ (HRS) in andrological patients with infertility, HIV infection and metab…

2013

Summary As commonly used self-reported screening instruments for male hypogonadism demonstrated lack of specificity, a Hypogonadism Related Symptom Scale (HRS) was developed in 2009 as a novel self-rating screening tool. As the questionnaire has not been validated, the purpose of our study was to perform a validation in patients presenting with different disorders (e.g. infertility, HIV infection or metabolic syndrome) and disease-related risk to develop hypogonadism. Two hundred and eighteen patients aged 19–71 years (40.1 ± 9.5) who completed the HRS and other common questionnaires [International Index Of Erectile Function (IIEF), National Institutes of Health Chronic Prostatitis Symptom …

AdultMaleInfertilitymedicine.medical_specialtyUrologyHuman immunodeficiency virus (HIV)ProstatitisHIV Infectionsmedicine.disease_causeHospital Anxiety and Depression ScaleSensitivity and SpecificitySeverity of Illness IndexYoung AdultEndocrinologyCronbach's alphaSex Hormone-Binding GlobulinSurveys and QuestionnairesInternal medicinemedicineHumansTestosteroneAgedMetabolic SyndromeGynecologybusiness.industryHypogonadismTestosterone (patch)General MedicineLuteinizing HormoneMiddle Agedmedicine.diseaseFollicle Stimulating HormoneSymptom AssessmentMetabolic syndromeLuteinizing hormonebusinessAndrologia
researchProduct